On November 15, 2018, Kettle, Jason Grant; Bagal, Sharanjeet Kaur; Boyd, Scott; Eatherton, Andrew John; Fillery, Shaun Michael; Robb, Graeme Richard; Raubo, Piotr Antoni published a patent.Category: imidazoles-derivatives The title of the patent was Preparation of heteroaryl compounds as inhibitors as G12C mutant RAS proteins. And the patent contained the following:
The invention relates to compounds of formula I and pharmaceutically acceptable salts thereof; their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders. Compounds of formula I wherein ring A is aryl, monocyclic heteroaryl and bicyclic heteroaryl; R1 is C1-4 alkyl, halo, OH, etc.; n is 0 – 3; W is N and CR13; X is O and NR14; Y is CR15R16, CO, COCR21R22; R2 is H, CN, halo, etc.; R3 is H, C1-3 fluoroalkyl, OH and derivatives, etc.; R4 is H and Me, R5 is H and Me; R6 is H and CH2NMe2; R13 is H, C1-4 alkyl, halo, etc.; R15, R16 are independently H and C1-3 alkyl; R21 and R22 are independently H, C1-3 alkyl, and F; and pharmaceutically acceptable salt thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their KRas protein inhibitory activity (some data given). The experimental process involved the reaction of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one(cas: 40644-16-4).Category: imidazoles-derivatives
The Article related to pyrazinooxazepinoquinazoline preparation g12c mutant ras protein inhibitor anticancer, Heterocyclic Compounds (More Than One Hetero Atom): Other 7-Membered Rings and other aspects.Category: imidazoles-derivatives
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem